Mitochondrial Dysfunction Therapeutics

JanusQ is an early-stage company developing peptide-based therapies that target mitochondrial dysfunction in neurodegenerative diseases. With two lead peptides showing strong efficacy in animal models of Alzheimer’s and Huntington’s Diseases (AD and HD), we are well positioned to drive towards the clinic in pursuit of treatments for these debilitating and, ultimately, fatal diseases.

JQ-H3 - Huntington's Disease

JQ-H3 blocks a pathological interaction between mutant huntingtin protein (mtHtt) with the mitochondrion, thereby preventing degradation of mitochondria and degeneration of neurons. Early intervention in this cascade with JQ-H3 delays the onset of Huntington' Disease (HD) and extends patient life.

JQ-A1 - Alzheimer's Disease

JQ-A1 prevents the aberrant association of two mitochondrial proteins that, otherwise, would lead to mitochondrial fragmentation and neuronal cell death. Treatment with JQ-A1 also improves brain cholesterol metabolism. The result is markedly improved behavioral and neurological outcomes, in both AD and HD.

JQ-P2 - Parkinson's Disease

JQ-P2 blocks the toxic effects of α-Synuclein inside the mitochondria of Parkinson's Disease (PD) affected neurons. By treating patients early, JQ-P2 will ameliorate PD onset and progression.